Early-stage embryos with abnormalities may still develop into healthy babies, study shows
- Date:
- March 29, 2016
- Source:
- University of Cambridge
- Summary:
- Abnormal cells in the early embryo are not necessarily a sign that a baby will be born with a birth defect such as Down's syndrome, suggests new research carried out in mice. Scientists show that abnormal cells are eliminated and replaced by healthy cells, repairing -- and in many cases completely fixing -- the embryo.
- Share:
Abnormal cells in the early embryo are not necessarily a sign that a baby will be born with a birth defect such as Down's syndrome, suggests new research carried out in mice at the University of Cambridge. In a study published today in the journal Nature Communications, scientists show that abnormal cells are eliminated and replaced by healthy cells, repairing -- and in many cases completely fixing -- the embryo.
Researchers at the Department of Physiology, Development and Neuroscience at Cambridge report a mouse model of aneuploidy, where some cells in the embryo contain an abnormal number of chromosomes. Normally, each cell in the human embryo should contain 23 pairs of chromosomes (22 pairs of chromosomes and one pair of sex chromosomes), but some can carry multiple copies of chromosomes, which can lead of developmental disorders. For example, children born with three copies of chromosome 21 will develop Down's syndrome.
Pregnant mothers -- particular older mothers, whose offspring are at greatest risk of developing such disorders -- are offered tests to predict the likelihood of genetic abnormalities. Between the 11th and 14th weeks of pregnancy, mothers may be offered chorionic villus sampling (CVS), a test that involves removing and analysing cells from the placenta. A later test, known as amniocentesis, involves analysing cells shed by the fetus into the surrounding amniotic fluid -- this test is more accurate, but is usually carried out during weeks 15-20 of the pregnancy, when the fetus is further developed.
Professor Magdalena Zernicka-Goetz, the study's senior author, was inspired to carry out the research following her own experience when pregnant with her second child. "I am one of the growing number of women having children over the age of 40 -- I was pregnant with my second child when I was 44," says Professor Zernicka-Goetz.
At the time, a CVS test found that as many as a quarter of the cells in the placenta that joined her and her developing baby were abnormal: could the developing baby also have abnormal cells? When Professor Zernicka-Goetz spoke to geneticists about the potential implications, she found that very little was understood about the fate of embryos containing abnormal cells and about the fate of these abnormal cells within the developing embryos.
Fortunately for Professor Zernicka-Goetz, her son, Simon, was born healthy. "I know how lucky I was and how happy I felt when Simon was born healthy," she says.
"Many expectant mothers have to make a difficult choice about their pregnancy based on a test whose results we don't fully understand," says Professor Zernicka-Goetz. "What does it mean if a quarter of the cells from the placenta carry a genetic abnormality -- how likely is it that the child will have cells with this abnormality, too? This is the question we wanted to answer. Given that the average age at which women have their children is rising, this is a question that will become increasingly important."
"In fact, abnormal cells with numerical and/or structural anomalies of chromosomes have been observed in as many as 80-90% of human early stage embryos following in vitro fertilization," says Professor Thierry Voet from the Wellcome Trust Sanger Institute, UK, and the University of Leuven, Belgium, another senior author of this paper, "and CSV tests may expose some degree of these abnormalities."
In research funded by the Wellcome Trust, Professor Zernicka-Goetz and colleagues developed a mouse model of aneuploidy by mixing 8-cell stage mouse embryos in which the cells were normal with embryos in which the cells were abnormal. Abnormal mouse embryos are relatively unusual, so the team used a molecule known as reversine to induce aneuploidy.
In embryos where the mix of normal and abnormal cells was half and half, the researchers observed that the abnormal cells within the embryo were killed off by 'apoptosis', or programmed-cell death, even when placental cells retained abnormalities. This allowed the normal cells to take over, resulting in an embryo where all the cells were healthy. When the mix of cells was three abnormal cells to one normal cell, some of abnormal cells continued to survive, but the ratio of normal cells increased.
"The embryo has an amazing ability to correct itself," explains Professor Zernicka-Goetz. "We found that even when half of the cells in the early stage embryo are abnormal, the embryo can fully repair itself. If this is the case in humans, too, it will mean that even when early indications suggest a child might have a birth defect because there are some, but importantly not all abnormal cells in its embryonic body, this isn't necessarily the case."
The researchers will now try to determine the exact proportion of healthy cells needed to completely repair an embryo and the mechanism by which the abnormal cells are eliminated.
Story Source:
Materials provided by University of Cambridge. The original story is licensed under a Creative Commons Licence. Note: Content may be edited for style and length.
Journal Reference:
- Helen Bolton, Sarah J. L. Graham, Niels Van der Aa, Parveen Kumar, Koen Theunis, Elia Fernandez Gallardo, Thierry Voet, Magdalena Zernicka-Goetz. Mouse model of chromosome mosaicism reveals lineage-specific depletion of aneuploid cells and normal developmental potential. Nature Communications, 2016; 7: 11165 DOI: 10.1038/ncomms11165
Cite This Page: